Search for content, post, videos

Pre-Market Stocks Briefing:Equinix Inc (EQIX), KaloBios Pharmaceuticals Inc (KBIO), Regeneron Pharmaceuticals Inc (REGN)

U.S. stock futures were pointing to a Wall Street rebound on Friday after the previous session saw the biggest selloff of equities in more than two months.

Investors on Friday were awaiting U.S. jobs data that could influence whether the Federal Reserve hikes interest rates when it meets in less than two weeks.

European stocks were in negative territory Friday, with investors still showing their disappointment with the less aggressive than expected cut in European Central Bank interest rates.

Asian shares ended Friday’s session sharply lower.

The economic calendar in the U.S. on Friday includes the U.S. Nonfarm Payrolls Report for November at 8:30 a.m. EST, and the Trade Balance for October at 8:30 a.m.

Economists surveyed by Reuters forecast nonfarm payrolls to rise 200,000 in November, adding to the 271,000 jobs created in October.

The unemployment rate is expected to hold at a 7-1/2-year low of 5%.

“The U.S. economy is solid, and the Fed raising rates is just a consequence of it,” said Thomas Stucki, chief investment officer at St. Galler Kantonalbank AG. “The labor market must really surprise by a large amount to have a big impact and push stocks lower. U.S. equities will outperform next year.”

U.S. stocks on Thursday closed with their worst losses since late September and the S&P 500 turned negative for the year after the ECB’s modest action on rates. The S&P 500 closed down 1.5%, the Dow Jones Industrial Average slid 1.4%, and the Nasdaq fell 1.7%.

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) stock on Friday’s pre market session gained 33.02% at price of $39.00. Over the last one month and the previous three months, KaloBios Pharmaceuticals Inc’s shares have rose 1419.17% and ticked up 867.66%, respectively. Additionally, the stock has surged 111.85% since the beginning of 2015. The company’s shares are trading above their 50-day and 200-day moving averages by 351.99% and 571.00%, respectively. KaloBios Pharmaceuticals Inc’s stock has a Relative Strength Index (RSI) of 63.25. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) recently proclaimed it has entered definitive agreements with institutional and accredited investors in connection with a private placement, or PIPE financing. Upon closing of the transaction, the Company will receive gross proceeds of approximately $8.2 million in exchange for the issuance to investors of 280,170 shares of common stock of the Company. The Company may increase the number of shares sold based on additional definitive agreements that may be received.  Closing of the transaction is anticipated to occur the week of December 7, 2015 and is subject to customary closing conditions.

Is KBIO a Solid Investment at These Levels? Read This Report For Details

To receive alerts before the crowd, text the word “STOCKS” to “33733”

On Friday’s pre market session, shares in Equinix Inc (NASDAQ:EQIX) rose 1.62% at the price of $300.00. Equinix Inc’s shares have declined -1.37% in the last one month, 11.89% in the previous three months and 38.14% on YTD basis. The company is trading 3.07% up its 50-day moving average and 15.40% above its 200-day moving average. Moreover, shares of Equinix Inc have an RSI of 52.35. Equinix Inc (NASDAQ:EQIX) the global interconnection and data center company, announced on December 3, 2015 that EarthLink is leveraging the Equinix Cloud Exchange™ for direct connectivity to cloud and enterprise customers as part of the EarthLink Cloud Express™ product.  As a leading managed network, security and cloud solutions provider EarthLink has been able to increase time to market and scale where the Equinix Cloud Exchange is available to meet their changing business needs.

How Should Investors Trade EQIX Now? Don’t Miss out a Special Trend Analysis

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stocks plummeted -1.92% in today’s pre market session with the price of $525.46. Over the last one month and over the past three months, Regeneron Pharmaceuticals Inc’s shares have lost -7.31% and 5.35%, respectively. Furthermore, the stock has jumped 30.59% since the start of this year. The company’s shares are trading 0.32% above their 50-day moving average. Additionally, Regeneron Pharmaceuticals Inc has an RSI of 44.10 and beta of 0.95. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced on November 24, 2015 that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular (CV) benefits of Praluent® (alirocumab) Injection after an acute coronary syndrome (ACS). The 18,000-patient OUTCOMES trial is expected to be completed in 2017. Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Can REGN Show a Strong Recovery? Find out in This Research Report

To receive alerts before the crowd, text the word “STOCKS” to “33733”